Atlas Wealth LLC Boosts Holdings in Thermo Fisher Scientific Inc. $TMO

Atlas Wealth LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 804.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,880 shares of the medical research company’s stock after buying an additional 32,801 shares during the quarter. Thermo Fisher Scientific comprises 2.2% of Atlas Wealth LLC’s portfolio, making the stock its 15th largest position. Atlas Wealth LLC’s holdings in Thermo Fisher Scientific were worth $18,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after acquiring an additional 288,296 shares during the period. J. Stern & Co. LLP increased its stake in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. State Street Corp lifted its holdings in shares of Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Capital World Investors grew its stake in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after buying an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Thermo Fisher Scientific by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after buying an additional 26,425 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $532.17 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $403.36 and a 12-month high of $643.99. The firm has a market capitalization of $197.77 billion, a price-to-earnings ratio of 29.26, a price-to-earnings-growth ratio of 2.41 and a beta of 0.87. The firm has a 50 day moving average of $484.57 and a 200 day moving average of $514.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a report on Thursday, May 14th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $602.14.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.